1. Home
  2. KLTO vs CHRO Comparison

KLTO vs CHRO Comparison

Compare KLTO & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLTO
  • CHRO
  • Stock Information
  • Founded
  • KLTO 2019
  • CHRO 2002
  • Country
  • KLTO United States
  • CHRO United States
  • Employees
  • KLTO N/A
  • CHRO N/A
  • Industry
  • KLTO
  • CHRO
  • Sector
  • KLTO
  • CHRO
  • Exchange
  • KLTO NYSE
  • CHRO Nasdaq
  • Market Cap
  • KLTO 9.8M
  • CHRO 11.3M
  • IPO Year
  • KLTO N/A
  • CHRO 2024
  • Fundamental
  • Price
  • KLTO $0.38
  • CHRO $1.68
  • Analyst Decision
  • KLTO
  • CHRO Strong Buy
  • Analyst Count
  • KLTO 0
  • CHRO 1
  • Target Price
  • KLTO N/A
  • CHRO N/A
  • AVG Volume (30 Days)
  • KLTO 185.8K
  • CHRO 104.9K
  • Earning Date
  • KLTO 03-04-2025
  • CHRO 03-04-2025
  • Dividend Yield
  • KLTO N/A
  • CHRO N/A
  • EPS Growth
  • KLTO N/A
  • CHRO N/A
  • EPS
  • KLTO N/A
  • CHRO N/A
  • Revenue
  • KLTO N/A
  • CHRO N/A
  • Revenue This Year
  • KLTO N/A
  • CHRO N/A
  • Revenue Next Year
  • KLTO N/A
  • CHRO N/A
  • P/E Ratio
  • KLTO N/A
  • CHRO N/A
  • Revenue Growth
  • KLTO N/A
  • CHRO N/A
  • 52 Week Low
  • KLTO $0.26
  • CHRO $0.45
  • 52 Week High
  • KLTO $13.10
  • CHRO $4.84
  • Technical
  • Relative Strength Index (RSI)
  • KLTO N/A
  • CHRO 50.49
  • Support Level
  • KLTO N/A
  • CHRO $1.59
  • Resistance Level
  • KLTO N/A
  • CHRO $1.99
  • Average True Range (ATR)
  • KLTO 0.00
  • CHRO 0.29
  • MACD
  • KLTO 0.00
  • CHRO -0.06
  • Stochastic Oscillator
  • KLTO 0.00
  • CHRO 41.44

About KLTO KLOTHO NEUROSCIENCES INC

Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.

About CHRO Chromocell Therapeutics Corporation

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Share on Social Networks: